Embryonal Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
Conditions: Esophageal Neoplasms; Lung Neoplasms; Mesothelioma; Thymus Neoplasms; Neoplasms, Germ Cell and Embryonal Intervention: Drug: Mithramycin Sponsor: National Cancer Institute (NCI) Recruiting - verified July 2016 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 6, 2016 Category: Research Source Type: clinical trials
